• ReShape Lifesciences Inc (NASDAQ: RSLS) has received FDA 510(k) clearance for the disposable Gastro Intestinal Balloon Indicator (GIBI HD) calibration tube for use in gastric and bariatric surgical procedures.

• The company expects U.S. commercial sales to begin in September 2022.

• The GIBI HD includes three new sizes – 32, 36, and 40 Fr – all designed to simplify bariatric procedures such as laparoscopic sleeve gastrectomy, gastric bypass, and adjustable gastric banding.

• The company says that GIBI HD is a multifunctional device compared to reusable bougies and disposable gastric tubes. The GIBI HD is also less traumatic to the patient, as it is intended to fit the lesser curvature of the stomach more easily and quickly reach the pylorus.

• Price Action: RSLS shares are up 18.47% at $0.58 during the market session on the last check Wednesday.

See more from Benzinga

• Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial

• GSK Confirms Rotavirus Vaccine Shortage, Hits Four African Countries: Report

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.